Zacks Small Cap Weighs in on Cosmos Health FY2025 Earnings

Cosmos Health Inc. (NASDAQ:COSM) – Zacks Small Cap issued their FY2025 earnings per share (EPS) estimates for Cosmos Health in a report released on Tuesday, January 13th. Zacks Small Cap analyst B. Sorensen anticipates that the company will earn ($0.25) per share for the year. The consensus estimate for Cosmos Health’s current full-year earnings is ($0.78) per share. Zacks Small Cap also issued estimates for Cosmos Health’s Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.11) EPS, Q1 2027 earnings at $0.00 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at $0.03 EPS and FY2027 earnings at $0.07 EPS.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The firm had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%.

A number of other equities analysts also recently weighed in on the company. Wall Street Zen raised Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Cosmos Health Stock Up 21.5%

Shares of Cosmos Health stock opened at $0.54 on Thursday. The business’s 50 day simple moving average is $0.56 and its 200 day simple moving average is $0.73. Cosmos Health has a 52-week low of $0.28 and a 52-week high of $1.32. The firm has a market cap of $20.28 million, a PE ratio of -0.72 and a beta of 5.37. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.84 and a current ratio of 0.99.

Institutional Trading of Cosmos Health

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC increased its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 225,507 shares of the company’s stock after acquiring an additional 128,776 shares during the quarter. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 as of its most recent SEC filing. 12.61% of the stock is owned by institutional investors.

Insider Activity at Cosmos Health

In other news, CEO Grigorios Siokas bought 493,495 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average cost of $0.45 per share, with a total value of $222,072.75. Following the completion of the purchase, the chief executive officer owned 7,738,474 shares of the company’s stock, valued at $3,482,313.30. This represents a 6.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders purchased 1,579,590 shares of company stock valued at $805,169. Corporate insiders own 25.10% of the company’s stock.

More Cosmos Health News

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Material CEO insider buying — CEO Grigorios Siokas disclosed a purchase of 493,495 shares at ~$0.45 on Jan. 14 (raising his stake by ~6.8%), adding to multiple buys earlier in January. Insider accumulation signals management confidence and likely helped lift the stock. Insider SEC Filing
• Positive Sentiment: Zacks Small‑Cap Research initiated coverage with a $4.50 per‑share valuation, highlighting vertical integration, U.S. expansion (ZipDoctor, Sky Premium Life), AI R&D (Cloudscreen), and projected revenue growth to ~$130M+ by 2027 — a bullish research catalyst that likely boosted sentiment. Zacks Initiation
• Positive Sentiment: Institutional interest — filings show several hedge funds/institutions (e.g., Citadel, Vanguard, Renaissance) added or increased positions in recent quarters, suggesting growing institutional attention that can support liquidity and price appreciation. Quiver Summary
• Neutral Sentiment: Zacks’ forward estimates show an eventual path to positive EPS (FY2027 ~$0.07) but are model‑driven and rely on execution, R&D progress, and U.S. expansion. These are upside scenarios rather than confirmed results. Zacks Estimates
• Negative Sentiment: Operating and profitability risks — recent quarterly results showed an EPS miss and negative margins/ROE; consensus still forecasts a full‑year loss (~‑$0.78), keeping near‑term earnings risk elevated. MarketBeat Financials
• Negative Sentiment: Valuation caveats and disclosure — Zacks used a high (20%) discount rate and Cosmos paid Zacks for the report; model assumptions and the sponsor disclosure increase execution and impartiality risk. Zacks Disclosure
• Negative Sentiment: High volatility and mixed sell‑side sentiment — small market cap, high beta and an average sell rating from brokers mean the stock can swing sharply; consider the higher risk profile before trading. MarketBeat Coverage

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.